AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1439067 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + nifedipine (CAP + NIF) 20 mg/12 h
Number of subjects: 80
Study 3540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 241
Study 3540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 241
Study 3540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg
Number of subjects: 241
Study 3540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 12 mg
Number of subjects: 241
Study 3540877 — intervention group
Group type: COMPARATOR
Intervention: Morphine 6 mg
Number of subjects: 241
Study 29976872 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (LIMIT trial)
Number of subjects: 721
Study 27040426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2mA for 20min during twenty days)
Number of subjects: 24
Study 27040426 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 27040426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS and Lokomat gait training
Number of subjects: 24
Study 27040426 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and Lokomat gait training
Number of subjects: 24
Study 24475799 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic arterial embolization (PAE)
Number of subjects: 114
Study 24475799 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 114
Study 22007041 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment with a multifactorial intervention lasting two years
Number of subjects: 781
Study 22007041 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 781
Study 19531276 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management plus treatment as usual (TAU) (n=31)
Number of subjects: 64
Study 19531276 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) control condition (n=33)
Number of subjects: 64
Study 18357475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sorbate (SA)
Number of subjects: 24
Study 18357475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% benzoate (BA)
Number of subjects: 24
Study 18357475 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine (CHX)
Number of subjects: 24
Study 18357475 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 24
Study 15824372 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir treatment
Number of subjects: 0
Study 15824372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11834104 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible magnet (700‐G intensity)
Number of subjects: 35
Study 11834104 — intervention group
Group type: COMPARATOR
Intervention: Sham magnet (placebo)
Number of subjects: 35
Study 11834104 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no magnet)
Number of subjects: 35
Study 10402766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 70 mg/m2 on day 1, fluorouracil 700 mg/m2 and leucovorin 20 mg/m2 on days 1 to 5)
Number of subjects: 42
Study 10402766 — intervention group
Group type: COMPARATOR
Intervention: Surgery (immediate surgery without chemotherapy)
Number of subjects: 42
Study 10402766 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 42
Study 7733763 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat protocol
Number of subjects: 70
Study 7733763 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat protocol
Number of subjects: 70
Study 2382805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and droperidol
Number of subjects: 40
Study 2382805 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and droperidol
Number of subjects: 40
Study 6114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol 3 mg thrice daily
Number of subjects: 30
Study 6114884 — intervention group
Group type: COMPARATOR
Intervention: Carbuterol 2 mg thrice daily
Number of subjects: 30
Study 6114884 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg thrice daily
Number of subjects: 30
Study 31285359 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic case-finding programme
Number of subjects: 1
Study 31285359 — intervention group
Group type: COMPARATOR
Intervention: Current routine diagnostic process
Number of subjects: 1
Study 28050801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (D4)
Number of subjects: 69
Study 28050801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (D10)
Number of subjects: 69
Study 28050801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline [NS])
Number of subjects: 69
Study 25262375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video about intrauterine devices (IUDs)
Number of subjects: 315
Study 23059868 — intervention group
Group type: EXPERIMENTAL
Intervention: CADENCE
Number of subjects: 180
Study 23059868 — intervention group
Group type: COMPARATOR
Intervention: SELF
Number of subjects: 180
Study 23059868 — intervention group
Group type: COMPARATOR
Intervention: FREQUENCY
Number of subjects: 180
Study 21255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied Eutectic mixture of local anesthetics (EMLA) during tDCS stimulation
Number of subjects: 9
Study 21255753 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream during tDCS stimulation
Number of subjects: 9
Study 21255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 9
Study 21255753 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 9
Study 18974529 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeiss AT 030 (GATZ)
Number of subjects: 40
Study 18974529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inami L‐5110 (GATI)
Number of subjects: 40
Study 18974529 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GATZ and GATI
Number of subjects: 40
Study 17054744 — intervention group
Group type: EXPERIMENTAL
Intervention: New fixed combination of mefloquine and artesunate
Number of subjects: 500
Study 17054744 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of mefloquine and artesunate
Number of subjects: 500
Study 15189956 — intervention group
Group type: COMPARATOR
Intervention: β2-agonist (single dose)
Number of subjects: 33
Study 15189956 — intervention group
Group type: COMPARATOR
Intervention: β2-agonist (longer duration trials)
Number of subjects: 33
Study 11588611 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 18
Study 11588611 — intervention group
Group type: COMPARATOR
Intervention: 0.5 Hz rTMS
Number of subjects: 18
Study 11588611 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 9059105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.25% in Entonox
Number of subjects: 35
Study 9059105 — intervention group
Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 35
Study 8404107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 to 25 micrograms/kg/min)
Number of subjects: 32
Study 8404107 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (0.5 to 5.0 micrograms/kg/min)
Number of subjects: 32
Study 8404107 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine added after dopamine failure
Number of subjects: 32
Study 3777548 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate normovolaemic haemodilution induced with a colloid solution (Plasmion)
Number of subjects: 40
Study 31461801 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg dexmedetomidine
Number of subjects: 90
Study 31461801 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MgSO4
Number of subjects: 90
Study 31461801 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 90
Study 29119631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start deferiprone (ES-DFP) at a low dose (50 mg/kg/day)
Number of subjects: 64
Study 29119631 — intervention group
Group type: COMPARATOR
Intervention: Delay chelation (DC)
Number of subjects: 64
Study 29119631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start deferiprone (ES-DFP)
Number of subjects: 64
Study 27819429 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) regarding student drinking and other college parents' alcohol-related communication
Number of subjects: 399
Study 27819429 — intervention group
Group type: COMPARATOR
Intervention: General college health norm information
Number of subjects: 399
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <18.5
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 18.5 - 25
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25 - 29
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥30
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 levels
Number of subjects: 483
Study 25266049 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG < 2
Number of subjects: 483
Study 22981555 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily for 6 weeks
Number of subjects: 21
Study 20353120 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection at Neiguan (PC 6) with 2.5 mg Droperidol (1 mL)
Number of subjects: 120
Study 20353120 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection with 1 mL Droperidol
Number of subjects: 120
Study 20353120 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 18718815 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen)
Number of subjects: 404
Study 18718815 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (without zoledronic acid)
Number of subjects: 404
Study 18718815 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid)
Number of subjects: 404
Study 18718815 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (without zoledronic acid)
Number of subjects: 404
Study 15981721 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH‐3D sequence with center of k-space acquisition after 8.7 s
Number of subjects: 20
Study 15981721 — intervention group
Group type: COMPARATOR
Intervention: FLASH‐3D sequence with center of k-space acquisition after 0.5 s
Number of subjects: 20
Study 12860219 — intervention group
Group type: EXPERIMENTAL
Intervention: berberine 1.2 to 2.0 g/day
Number of subjects: 156
Study 12860219 — intervention group
Group type: EXPERIMENTAL
Intervention: berberine
Number of subjects: 156
Study 12860219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 156
Study 11028252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RGD891
Number of subjects: 0
Study 8622227 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 39
Study 8622227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 39
Study 8622227 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 39
Study 8622227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 39
Study 1815231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel dressings
Number of subjects: 107
Study 1815231 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 107
Study 6360400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg single oral dose)
Number of subjects: 20
Study 6360400 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (2 tablets, each containing 500 mg of sulfadoxine plus 25 mg of pyrimethamine)
Number of subjects: 20
Study 31038979 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich PRP (LR-PRP)
Number of subjects: 57
Study 31038979 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor PRP (LP-PRP)
Number of subjects: 57
Study 31038979 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 57
Study 30152291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0
Study 30152291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26398741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-CRM (ACWY2)
Number of subjects: 715
Study 26398741 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of placebo followed by 1 dose of MenACWY-CRM (ACWY1)
Number of subjects: 715
Study 24876616 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous pump and CGM initiation
Number of subjects: 20
Study 24876616 — intervention group
Group type: COMPARATOR
Intervention: Standard pump therapy with delayed CGM initiation
Number of subjects: 20
Study 22252825 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg once daily (QD)
Number of subjects: 19
Study 22252825 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg once daily (QD)
Number of subjects: 19
Study 22252825 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (BID)
Number of subjects: 19
Study 18971247 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 0.72 mg/24 h
Number of subjects: 154
Study 18971247 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate 1.44 mg/24 h
Number of subjects: 154
Study 18971247 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate 3.6 mg/24 h
Number of subjects: 154
Study 18971247 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch application
Number of subjects: 154
Study 17497969 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamped drain group
Number of subjects: 66
Study 17497969 — intervention group
Group type: COMPARATOR
Intervention: Continuous suction drainage group
Number of subjects: 66
Study 15905658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 75
Study 12498842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.2 mg/mL), applied topically with a soaked microsponge for 2 minutes after PRK
Number of subjects: 60
Study 12498842 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with mitomycin-C)
Number of subjects: 60
Study 12498842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.2 mg/mL)
Number of subjects: 60
Study 9620109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 9620109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 9620109 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 0
Study 9620109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0
Study 9620109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Moexipril
Number of subjects: 0
Study 8208874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus early morning sleep deprivation
Number of subjects: 16
Study 8208874 — intervention group
Group type: COMPARATOR
Intervention: Lithium plus control sleep deprivation
Number of subjects: 16
Study 8208874 — intervention group
Group type: COMPARATOR
Intervention: Desipramine with early morning sleep deprivation
Number of subjects: 16
Study 8208874 — intervention group
Group type: COMPARATOR
Intervention: Desipramine with control sleep deprivation
Number of subjects: 16
Study 2645415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine + DEC
Number of subjects: 107
Study 2645415 — intervention group
Group type: COMPARATOR
Intervention: DEC alone
Number of subjects: 107
Study 30558984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with oral ciprofloxacin (2 doses prior to urinary catheter removal)
Number of subjects: 167
Study 30558984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics prior to urinary catheter removal)
Number of subjects: 167
Study 30558984 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with oral ciprofloxacin
Number of subjects: 167
Study 28499433 — intervention group
Group type: EXPERIMENTAL
Intervention: ServAR
Number of subjects: 90
Study 28499433 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information on standard serving sizes
Number of subjects: 90
Study 28499433 — intervention group
Group type: COMPARATOR
Intervention: No information/aid (control)
Number of subjects: 90
Study 25183287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg kg(‐1) h(‐1))
Number of subjects: 45
Study 25183287 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg kg(‐1) h(‐1))
Number of subjects: 45
Study 25183287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 45
Study 22405257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM)
Number of subjects: 60
Study 22405257 — intervention group
Group type: COMPARATOR
Intervention: Topical mydriatics (TM)
Number of subjects: 60
Study 21425144 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with loop electrical excision procedure (LEEP)
Number of subjects: 415
Study 21425144 — intervention group
Group type: COMPARATOR
Intervention: Colposcopic follow-up for 18 months
Number of subjects: 415
Study 20394132 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video assignment (experimental group, n = 42)
Number of subjects: 84
Study 20394132 — intervention group
Group type: COMPARATOR
Intervention: No online video assignment (control group, n = 42)
Number of subjects: 84
Study 20394132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 84
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy by antiandrogens
Number of subjects: 0
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Antineoplastic chemotherapeutic agents such as estramustine and taxanes
Number of subjects: 0
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies including systemic therapy before or after local treatment
Number of subjects: 0
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 0
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of rapamycin and its analogs
Number of subjects: 0
Study 17310835 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approach strategies
Number of subjects: 0
Study 15557515 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 97
Study 15557515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 11984381 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing care interventions
Number of subjects: 148
Study 9672930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tenoxicam 0.75 mg.kg‐1
Number of subjects: 50
Study 9672930 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate 0.2 mg.kg‐1
Number of subjects: 50
Study 7513776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (30,000 U/kg after induction of anesthesia, 30,000 U/kg added to the prime of the cardiopulmonary bypass)
Number of subjects: 30
Study 7513776 — intervention group
Group type: COMPARATOR
Intervention: Control group (without aprotinin)
Number of subjects: 30
Study 7513776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30
Study 7513776 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin and Control
Number of subjects: 30
Study 2661444 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenzan‐Fumero pump
Number of subjects: 87
Study 2661444 — intervention group
Group type: COMPARATOR
Intervention: Conventional roller pump
Number of subjects: 87
Study 1215545 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl prostaglandin F2alpha injected intra-amniotically
Number of subjects: 0
Study 1215545 — intervention group
Group type: COMPARATOR
Intervention: PGF2Alpha (comparison group)
Number of subjects: 0
Study 31807987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session
Number of subjects: 31
Study 31807987 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical rehabilitation (CON)
Number of subjects: 31
Study 30686636 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 28 days
Number of subjects: 22
Study 30686636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 22
Study 30686636 — intervention group
Group type: COMPARATOR
Intervention: Comparison of atorvastatin vs placebo
Number of subjects: 22
Study 27080326 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (DT)
Number of subjects: 164
Study 27080326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (BT)
Number of subjects: 164
Study 27080326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 164
Study 27080326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pelvic floor rehabilitation (CPFR)
Number of subjects: 164
Study 26498129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (∼14 g day(‐1) NaCl)
Number of subjects: 54
Study 26498129 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, non-selective COX-1 and COX-2 inhibitor)
Number of subjects: 54
Study 26498129 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg, selective COX-2 inhibitor)
Number of subjects: 54
Study 26498129 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (<2.3 g day(‐1) NaCl)
Number of subjects: 54
Study 23909286 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal homeostasis model assessment of insulin resistance at the 32nd week of gestation
Number of subjects: 208
Study 23909286 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum triglycerides during pregnancy
Number of subjects: 208